Aescap Venture

F-Star Therapeutics is a biopharmaceutical company focused on developing novel bispecific antibody products aimed at improving upon current standards of care, particularly in cancer therapy. The company is uniquely positioned with a strong patent portfolio, enabling it to create and develop Fcab antibody fragments and bispecific antibodies by modifying the constant region of an antibody. F-Star's Modular Antibody Technology allows for rapid discovery and development of bispecific antibodies by adding binding sites to the constant region, facilitating easier production compared to other antibody formats. The company is leveraging this technology to build a pipeline of product candidates. Founded in 2006, F-Star has received significant funding from leading venture capital firms and strategic corporate investors. The company operates out of Cambridge, UK, with over 35 employees dedicated to research and development.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

i-Optics, established in 2006, is a Dutch medical device company specializing in corneal diagnostic solutions. It offers the Cassini Corneal Shape Analyzer, a pioneering tool using color LED technology to precisely measure corneal astigmatism, enhancing premium IOL planning. Additionally, i-Optics provides the EasyScan, a zero-dilation retinal imaging system for diagnosing retinal diseases. Their suite of examinations, including corneal topography, pupillometry, and full-color photography, empowers cataract surgeons to better understand corneal properties, improve surgical outcomes, and increase patient satisfaction.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Avantium is a Dutch technology company specializing in advanced high-throughput research and development for energy, chemicals, and pharmaceutical industries. Headquartered in Amsterdam with state-of-the-art laboratories, Avantium's proprietary technology accelerates product and process innovation while reducing costs. With over 70 global clients, including industry leaders, Avantium has proven its technology's validity and commercial viability. The company focuses on developing new biofuels, bio-based chemicals, and novel crystal forms of marketed drugs under patent. Its team comprises highly educated professionals in catalysis, crystallography, organic chemistry, engineering, statistics, cheminformatics, and software development, collaborating closely with partner R&D organizations to drive innovation.

F-Star Therapeutics is a biopharmaceutical company focused on developing novel bispecific antibody products aimed at improving upon current standards of care, particularly in cancer therapy. The company is uniquely positioned with a strong patent portfolio, enabling it to create and develop Fcab antibody fragments and bispecific antibodies by modifying the constant region of an antibody. F-Star's Modular Antibody Technology allows for rapid discovery and development of bispecific antibodies by adding binding sites to the constant region, facilitating easier production compared to other antibody formats. The company is leveraging this technology to build a pipeline of product candidates. Founded in 2006, F-Star has received significant funding from leading venture capital firms and strategic corporate investors. The company operates out of Cambridge, UK, with over 35 employees dedicated to research and development.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Avantium is a Dutch technology company specializing in advanced high-throughput research and development for energy, chemicals, and pharmaceutical industries. Headquartered in Amsterdam with state-of-the-art laboratories, Avantium's proprietary technology accelerates product and process innovation while reducing costs. With over 70 global clients, including industry leaders, Avantium has proven its technology's validity and commercial viability. The company focuses on developing new biofuels, bio-based chemicals, and novel crystal forms of marketed drugs under patent. Its team comprises highly educated professionals in catalysis, crystallography, organic chemistry, engineering, statistics, cheminformatics, and software development, collaborating closely with partner R&D organizations to drive innovation.

F-Star Therapeutics is a biopharmaceutical company focused on developing novel bispecific antibody products aimed at improving upon current standards of care, particularly in cancer therapy. The company is uniquely positioned with a strong patent portfolio, enabling it to create and develop Fcab antibody fragments and bispecific antibodies by modifying the constant region of an antibody. F-Star's Modular Antibody Technology allows for rapid discovery and development of bispecific antibodies by adding binding sites to the constant region, facilitating easier production compared to other antibody formats. The company is leveraging this technology to build a pipeline of product candidates. Founded in 2006, F-Star has received significant funding from leading venture capital firms and strategic corporate investors. The company operates out of Cambridge, UK, with over 35 employees dedicated to research and development.

to-BBB is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines existing drugs with to-BBB’s proprietary G-Technology® for enhanced drug delivery across the blood-brain barrier. to-BBB currently has two products in clinical trials: its lead product 2B3-101 is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases; the second product 2B3-201 for MS relapses and other neuroinflammatory diseases is completing a Phase I clinical study. to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

i-Optics, established in 2006, is a Dutch medical device company specializing in corneal diagnostic solutions. It offers the Cassini Corneal Shape Analyzer, a pioneering tool using color LED technology to precisely measure corneal astigmatism, enhancing premium IOL planning. Additionally, i-Optics provides the EasyScan, a zero-dilation retinal imaging system for diagnosing retinal diseases. Their suite of examinations, including corneal topography, pupillometry, and full-color photography, empowers cataract surgeons to better understand corneal properties, improve surgical outcomes, and increase patient satisfaction.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.

Affectis Pharmaceuticals is a company focused on developing innovative drugs to treat neurodegenerative, neuroinflammatory, psychiatric, and inflammatory disorders. The firm utilizes research findings in the areas of depression, schizophrenia, and inflammation to discover and create new therapeutic options. Through its commitment to addressing these complex diseases, Affectis aims to advance healthcare solutions and improve patient outcomes.

F-Star Therapeutics is a biopharmaceutical company focused on developing novel bispecific antibody products aimed at improving upon current standards of care, particularly in cancer therapy. The company is uniquely positioned with a strong patent portfolio, enabling it to create and develop Fcab antibody fragments and bispecific antibodies by modifying the constant region of an antibody. F-Star's Modular Antibody Technology allows for rapid discovery and development of bispecific antibodies by adding binding sites to the constant region, facilitating easier production compared to other antibody formats. The company is leveraging this technology to build a pipeline of product candidates. Founded in 2006, F-Star has received significant funding from leading venture capital firms and strategic corporate investors. The company operates out of Cambridge, UK, with over 35 employees dedicated to research and development.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.

EOS is a biopharmaceutical company committed to the development of novel medicines for the treatment of cancer.EOS S.p.A. was founded in June 2006 by Silvano Spinelli, Gabriella Camboni, and Ennio Cavalletti along with Jacques Theurillat. Company’s operations were seed and further financed by founders and by Sofinnova Partners since its inception. EOS is a privately held organization headquartered in Via Monte di Pietà, 1/A, Milano, Italy.

ActoGeniX is a biopharmaceutical company established in 2006 and headquartered in Zwijnaarde, Belgium. It focuses on the development and commercialization of a new generation of biological drugs utilizing a proprietary technology platform. This platform employs living non-pathogenic microorganisms for the oral delivery of biopharmaceuticals, addressing unmet needs in gastrointestinal, immunological, and metabolic diseases. Through its innovative approach, ActoGeniX aims to advance therapeutic options in these critical areas of healthcare.

Avantium is a Dutch technology company specializing in advanced high-throughput research and development for energy, chemicals, and pharmaceutical industries. Headquartered in Amsterdam with state-of-the-art laboratories, Avantium's proprietary technology accelerates product and process innovation while reducing costs. With over 70 global clients, including industry leaders, Avantium has proven its technology's validity and commercial viability. The company focuses on developing new biofuels, bio-based chemicals, and novel crystal forms of marketed drugs under patent. Its team comprises highly educated professionals in catalysis, crystallography, organic chemistry, engineering, statistics, cheminformatics, and software development, collaborating closely with partner R&D organizations to drive innovation.

Vivendy Therapeutics Ltd. is dedicated to developing enzyme replacement therapies for Morbus Morquio, a rare lysosomal storage disease caused by a genetic deficiency. Founded in 2006 and headquartered in Basel, Switzerland, the company has created a specialized recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is engineered to enhance enzyme activity. This modification significantly improves the efficacy of the therapy for MPS IVA, aiming to provide better treatment options for patients affected by this condition.

ProtAffin is a biotechnology company in Austria developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures. ProtAffin's products are first-in-class engineered versions of human proteins which bind to cell surface glycans (sugars) to affect their biological activity. Activated versions of specific cell surface glycans underlie inflammatory processes in several diseases including rheumatoid arthritis, chronic obstructive pulmonary disorder, Crohn's disease and cancer and represent a rich and relatively under-investigated class of potential drug targets for the pharmaceutical and biotechnology industries. Protaffin's approach is entirely innovative and opens up glycans as druggable targets through the use of its CellJammer® discovery platform.

F-Star Therapeutics is a biopharmaceutical company focused on developing novel bispecific antibody products aimed at improving upon current standards of care, particularly in cancer therapy. The company is uniquely positioned with a strong patent portfolio, enabling it to create and develop Fcab antibody fragments and bispecific antibodies by modifying the constant region of an antibody. F-Star's Modular Antibody Technology allows for rapid discovery and development of bispecific antibodies by adding binding sites to the constant region, facilitating easier production compared to other antibody formats. The company is leveraging this technology to build a pipeline of product candidates. Founded in 2006, F-Star has received significant funding from leading venture capital firms and strategic corporate investors. The company operates out of Cambridge, UK, with over 35 employees dedicated to research and development.

Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.

to-BBB is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines existing drugs with to-BBB’s proprietary G-Technology® for enhanced drug delivery across the blood-brain barrier. to-BBB currently has two products in clinical trials: its lead product 2B3-101 is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases; the second product 2B3-201 for MS relapses and other neuroinflammatory diseases is completing a Phase I clinical study. to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

ProtAffin is a biotechnology company in Austria developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures. ProtAffin's products are first-in-class engineered versions of human proteins which bind to cell surface glycans (sugars) to affect their biological activity. Activated versions of specific cell surface glycans underlie inflammatory processes in several diseases including rheumatoid arthritis, chronic obstructive pulmonary disorder, Crohn's disease and cancer and represent a rich and relatively under-investigated class of potential drug targets for the pharmaceutical and biotechnology industries. Protaffin's approach is entirely innovative and opens up glycans as druggable targets through the use of its CellJammer® discovery platform.

ActoGeniX is a biopharmaceutical company established in 2006 and headquartered in Zwijnaarde, Belgium. It focuses on the development and commercialization of a new generation of biological drugs utilizing a proprietary technology platform. This platform employs living non-pathogenic microorganisms for the oral delivery of biopharmaceuticals, addressing unmet needs in gastrointestinal, immunological, and metabolic diseases. Through its innovative approach, ActoGeniX aims to advance therapeutic options in these critical areas of healthcare.

Affectis Pharmaceuticals is a company focused on developing innovative drugs to treat neurodegenerative, neuroinflammatory, psychiatric, and inflammatory disorders. The firm utilizes research findings in the areas of depression, schizophrenia, and inflammation to discover and create new therapeutic options. Through its commitment to addressing these complex diseases, Affectis aims to advance healthcare solutions and improve patient outcomes.